Shares of Capricor Therapeutics Inc. (CAPR) are down more than 40% from their 52-week high of $23.40, recorded last October, and trade around $13.
This biotechnology company is working on a new treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.